Should Employers Cover GLP-1 Drugs? 4 Key Facts to Consider

In the evolving landscape of metabolic health and weight management, GLP-1 drugs coverage decisions are top of mind for employers. The new Wegovy pill - the first GLP‑1 weight‑loss medication you can take by mouth - is creating even more interest in a drug category that was already booming. Many people who weren't comfortable with injections may now take a closer look, simply because a daily pill feels easier and more familiar. With that growing interest comes a lot of important questions about GLP-1 drugs coverage, especially for employers balancing employee wellness with business costs.

The Rise of Oral GLP-1 Medications and Employer Implications

GLP-1 receptor agonists, such as semaglutide (found in Wegovy and Ozempic), mimic the glucagon-like peptide-1 hormone to regulate blood sugar, slow gastric emptying, and reduce appetite. This mechanism not only aids weight loss but also supports metabolic health conditions like type 2 diabetes and obesity-related comorbidities. The introduction of an oral version of Wegovy marks a pivotal shift, potentially broadening access by addressing injection aversion—a common barrier for patients.

Health plans and employers are watching this trend closely as more convenient options enter the market. Gary Petruzzelli, Vice President of Pharmacy Strategy & Services at Capital Blue Cross, says the new pill underscores why employers should look at the full set of considerations before deciding on coverage.

"The introduction of an oral GLP‑1 will likely increase demand even more, which makes it even more important for individuals to understand all the factors involved - including costs, side effects, and whether these medications are the right fit for their long‑term health goals," Petruzzelli said.

As interest expands, employers are facing important questions about overall cost, long‑term health outcomes, and how GLP-1 coverage fits into their broader benefits strategy. Obesity remains a significant driver of healthcare expenses, contributing to conditions like diabetes, hypertension, and cardiovascular disease, which affect workforce productivity. Covering GLP-1 drugs could address these issues, but only with careful evaluation.

4 Key Facts Employers Should Consider for GLP-1 Drugs Coverage

Before implementing or expanding GLP-1 drugs coverage, employers must weigh these evidence-based factors to ensure sustainable benefits design.

1. GLP-1 Coverage Can Be Costly

GLP-1 drugs can cost as much as $1,000 per month, and users of GLP-1s need to stay on the drugs long-term or the weight comes back. Those who stop taking them typically regain two-thirds of the weight they lost within a year. The hefty and recurring cost has led some employers to end or restrict coverage of GLP-1 drugs due to concerns about affordability for both employees and their businesses.

This pricing reflects the drugs' manufacturing complexity and clinical trial investments, but it strains self-insured plans. Employers should analyze utilization forecasts, especially with oral options like Wegovy pill potentially driving higher uptake. Tools for symptom tracking, such as apps like Shotlee, can help employees monitor adherence and outcomes, potentially justifying costs through better data.

2. Side Effects Might Affect Productivity

It's well-documented that obesity can be a cost driver in employee healthcare, fueling absenteeism and undermining productivity. But GLP-1 drugs also have concerning and risky side effects - ranging from nausea, vomiting, and diarrhea to depression - that can lead to absenteeism or lost productivity.

Gastrointestinal issues often peak in the first weeks of treatment and may require dose titration. Mental health effects, though less common, warrant monitoring, particularly in employees with pre-existing conditions. Employers can mitigate this by pairing coverage with supportive resources like anti-nausea protocols or employee assistance programs, ensuring GLP-1 therapy enhances rather than hinders performance.

3. Some Have Trouble Staying on GLP-1s

Whether it's due to high cost, unwanted side effects, or both, the majority of people who start using GLP-1 drugs stop taking them before they see any meaningful health benefit. This can mean a costly expense with no tangible result.

Adherence rates for GLP-1s hover around 30-50% after one year, per real-world studies, underscoring the need for patient education and support. Employers might consider value-based contracts with pharmacies or prior authorization requiring lifestyle commitments to improve retention and ROI on GLP-1 drugs coverage.

4. A Drug Alone Won't Keep the Weight Off

GLP-1 drugs generally are not considered a standalone treatment for obesity, which often requires individual, comprehensive medical strategies and lifestyle changes. Exercise, behavioral changes, and even mental health counseling can be helpful to maintaining a healthy weight - and your healthcare plan can help make the difference.

Clinical guidelines from bodies like the American Diabetes Association emphasize multimodal approaches. Integrating GLP-1 coverage with wellness incentives, nutrition coaching, and fitness programs amplifies outcomes, turning medication into a catalyst for sustained health improvements.

How Capital Blue Cross Can Help Employers with GLP-1 Decisions

If you're an employer considering (or reconsidering) whether to cover GLP-1 drugs for your employees, taking a comprehensive look at your healthcare coverage can help you decide.

Capital Blue Cross, for instance, can provide in-depth consultations to employers who have its group coverage. Capital's medical experts examine cost and utilization data in addition to population health metrics to help employers identify healthcare-related issues impacting their employees. In addition, Capital can provide details regarding the prevalence of diabetes, high blood pressure and other conditions associated with being overweight to help employers make coverage decisions.

This insight can help businesses identify the most affordable, effective healthcare benefits and programs and better manage and support employee health and wellness. For individuals, Capital offers tools to lose weight, prevent diabetes, and even manage or reverse Type 2 diabetes. Capital also offers a wellness program that gives your employees financial incentives simply for taking care of themselves.

Practical Guidance for Employers on GLP-1 Integration

When evaluating GLP-1 drugs coverage, start with a population health assessment to gauge obesity prevalence and related comorbidities. Discuss with pharmacy benefit managers (PBMs) options like step therapy—requiring lifestyle interventions first—or caps on duration. Patient selection is key: those with BMI over 30 or diabetes may see the greatest benefit.

Safety monitoring includes baseline thyroid checks (due to rare risks) and regular follow-ups for gastrointestinal tolerance. Compared to alternatives like bariatric surgery or older weight-loss drugs, GLP-1s offer non-invasive efficacy but demand ongoing commitment.

Key Takeaways: What This Means for Employers

• High Costs Require Projections: Budget for $12,000+ annually per user, factoring in long-term use.
• Balance Productivity Risks: Support side effect management to avoid absenteeism.
• Prioritize Adherence: Combine drugs with coaching for better retention.
• Adopt Comprehensive Strategies: Pair GLP-1s with lifestyle programs for lasting results.

Medications like GLP-1 drugs might be a helpful tool for some, but there are a host of other health and wellness resources available for your employees - and your business.

Conclusion: Informed Coverage for a Healthier Workforce

GLP-1 drugs like the oral Wegovy pill hold promise for tackling obesity's toll on employee health, but employers must navigate costs, adherence, and holistic needs. By heeding these 4 facts and leveraging partners like Capital Blue Cross, you can craft benefits that promote wellness without compromising fiscal health. Consult your health plan today to align GLP-1 coverage with your workforce's unique profile.